Re‑Aim Therapeutics is a biotech start‑up developing functional cures for T cell–mediated autoimmune diseases.
Re-Aim Therapeutics has raised $9.4M in total funding. The most recent round was Seed. The last funding was announced in May 2026.
Re-Aim Therapeutics's investors include Oxford Science Enterprises, Syncona Partners LLP.
Re-Aim Therapeutics is headquartered in Headington, United Kingdom.
Re‑Aim Therapeutics is a biotech start‑up developing functional cures for T cell–mediated autoimmune diseases.
Re-Aim Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Re-Aim Therapeutics — Funding & Investors." VCBacked, May 18, 2026, https://www.vcbacked.co/company/re-aim-therapeutics. Accessed August 14, 2026.
VCBacked. (2026). Re-Aim Therapeutics — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/re-aim-therapeutics
{{cite web |title=Re-Aim Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/re-aim-therapeutics |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated